Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.47 |
| ▸ | MEN1 | O00255 | 6/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10959895 | 0.86 | NPSR1 (0.50) | KMT2AMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6626142 | 0.84 | KMT2A (0.46) | KMT2AMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5712822 | 0.83 | KMT2A (0.44) | KMT2AMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL9435677 | 0.83 | KMT2A (0.45) | KMT2AMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL11437979 | 0.83 | KMT2A (0.44) | KMT2AMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1530165 | 0.83 | ESR1 (0.39) | KMT2AMEN1CYP3A4ALDH1A1TSHR | |
| SCHEMBL2472803 | 0.81 | MEN1 (0.43) | KMT2AMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3831425 | 0.81 | CHRM5 (0.41) | KMT2AMEN1HTTL3MBTL1MAPT | |
| SCHEMBL11882082 | 0.81 | NPSR1 (0.45) | KMT2AMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL11016845 | 0.81 | KMT2A (0.44) | KMT2AMEN1CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4551570-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Dong-A ST Co., Ltd. (KR) | 2025-05-14 | — | — | EP | claimed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | claimed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| WO-2024009215-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-11 | — | — | WO | claimed |
| EP-4551570-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Dong-A ST Co., Ltd. (KR) | 2025-05-14 | — | — | EP | disclosed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| WO-2024009215-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-11 | — | — | WO | disclosed |
| CN-102056900-A | Compounds and compositions as modulators of GPR119 activity | IRM LLC | 2011-05-11 | — | — | CN | disclosed |
| EP-1109450-B1 | MICROCAPSULE FORMULATIONS | BAYER CROPSCIENCE AG (DE) | 2003-02-19 | — | — | EP | disclosed |
| EP-1109449-B1 | MICROCAPSULE FORMULATIONS | BAYER AG (DE) | 2002-11-06 | — | — | EP | disclosed |
| EP-1109450-A1 | MICROCAPSULE FORMULATIONS | BAYER AG (DE) | 2001-06-27 | — | — | EP | disclosed |
| EP-1109449-A1 | MICROCAPSULE FORMULATIONS | BAYER AG (DE) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000013503-A1 | MICROCAPSULE FORMULATIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-03-16 | — | — | WO | disclosed |
| WO-2000013504-A1 | MICROCAPSULE FORMULATIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-03-16 | — | — | WO | disclosed |
| EP-0031385-A1 | PROCESS FOR PREPARING POLYMETHYLENEPOLYPHENYL POLYCARBAMATE | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1981-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | KMT2A 4282/4885MEN1 1984/4885CYP3A4 2997/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | KMT2A 4282/4885MEN1 1984/4885CYP3A4 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.